




Drug Discovery & Development Symposium 2025

Inclusive & sustainable drug
development for Pulmonary
Arterial Hypertension (PAH)

16 - 17 June 2025

Mercure Amsterdam City Hotel
Joan Muyskenweg 10, 1096 CJ,
Amsterdam, Netherlands



Inclusive & sustainable drug development for PAH

08:00-08:25 Welcome tea & coffee

08:25-08:30 Welcome
Anna Hemnes, PVRI President 2024-2026

SESSION 1: New standards of care

Moderators: Anna Hemnes, Harm Jan Bogaard

08:30-09:00 Global perspective on regulatory approval of Sotatercept
Representatives from FDA: Mitchel Psocka (virtual), EMA (TBC)

09:00-09:20 How Sotatercept will change the treatment algorithm
Sean Gaine (TBC)

09:20-09:40 Implications of a new background therapy for drug development
Marion Delcroix

09:40-10:00 Panel & delegate discussion
All session speakers & moderators

SESSION 2: Disease modification

Moderators: David Montani, Roham Zamanian

10:00-10:15 How to define or prove disease modification
Mark Toshner

10:15-10:40 Pro/con debate: Drug development in the post vasodilator era - including a demonstration of disease modification
Pro: Mardi Gomberg / Con: Olivier Sitbon (TBC)

10:40-10:50 Panel & delegate discussion
All session speakers & moderators

10:50-11:10 Refreshment break

SESSION 3: Diversity & inclusion

Moderators: Gergely Meszaros, Esther Nossent

11:10-11:30 Addressing sex differences in treatment decisions & drug development
Deimante Hoppenot

11:30-11:50 How to include underrepresented patients into trials
Hannah Valentine (TBC)

11:50-12:00 Panel & delegate discussion
All session speakers & moderators

SESSION 4: Global aspects of drug development & availability

Moderators: Anton Noordegraaf, Deimante Hoppenot

- 12:00-12:15 Using the GoDeep Registry to prioritise & facilitate global drug trials
Werner Seeger
- 12:15-12:40 Pro/con debate: It is Big Pharma's responsibility to prioritise drug availability over drug discovery
Pro: Anna Hemnes / Con: Ardeshir Ghofrani (TBC)
- 12:40-13:00 Panel & delegate discussion
All session speakers & moderators

13:00-14:00 Lunch break

SESSION 5: Innovations in trial design

Moderators: Athénaïs Boucly, TBC

- 14:00-14:20 How to use risk scores (enrichment, endpoints)
Athénaïs Boucly
- 14:20-14:40 How to use imaging endpoints reflecting the pulmonary circulation & RV
David Kiely
- 14:40-15:10 n=1 trials & randomised withdrawal studies
Martin Wilkins
- 15:10-15:30 Panel & delegate discussion
All session speakers & moderators

15:30-15:50 Refreshment break

- 15:50-16:10 Novel statistical approaches: Bayesian statistics, use of win ratio
Alex Rothman
- 16:10-16:30 Practical & ethical aspects around OLE studies
Harm Jan Bogaard
- 16:30-16:50 Climate impact of drug development
Frances Varian
- 16:50-17:10 Panel & delegate discussion
All session speakers & moderators
- 17:10-19:00 Networking drinks reception

Scientific programme: 17 June

08:00-08:30 Welcome tea & coffee

SESSION 6: Novel drug & device therapies

Moderators: Frances de Man, Jurjan Aman

08:30-09:00 New drugs to modify TGF- β receptor signalling
Paul Yu

09:00-09:30 Pulmonary artery denervation
Alex Rothman

09:30-10:00 Elaphin
Roham Zamanian

10:00-10:30 Refreshment break

10:30-11:00 Mosliciguat
Ardeshir Ghofrani

11:00-11:30 Aria Device
Irene Lang (TBC)

11:30-12:00 Seralutinib
Pilar Escribano Subías

12:00-12:30 Closing statements

